BioMedNewsBreaks – Odyssey Health Inc. (ODYY) Featured in Stock2Me Podcast Spotlighting Two-Time Olympic Gold Medalist Abby Wambach

Odyssey Health (OTC: ODYY), formerly Odyssey Group International and a company focused on developing unique, life-saving medical products, is featured in the latest episode of InvestorBrandNetwork’s Stock2Me podcast. Hosted by Stuart Smith, the podcast talks with soccer play Abby Wambach, an Olympic gold medalist and member of ODYY’s sports advisory board. During the interview, Wambach discusses her soccer career and why she was drawn to Odyssey, a medical technology company that is developing a drug/device combination intended to treat concussion. Wambach and other members of the sports advisory board support the company’s efforts to enhance public awareness of traumatic brain injuries and concussions and the need for an FDA-approved therapy. The Stock2Me Podcast is part of IBN’s sustained effort to provide specialized content distribution via widespread syndication channels; the podcast features a variety of companies and individuals, many of whom are actively revolutionizing age-old business practices within their respective markets. “There’s just so little research done not only on concussions themselves but also when you break it down into the genders,” said ODYY sports advisory board member Abby Wambach in the press release. “So many less dollars get siphoned over to the women’s side, not only because it’s newer in terms of the history of sport, but because women historically haven’t been given the same amount of research dollars to figure out what’s going on with their bodies and why. . . . That’s why I partnered with Jake [Vanlandingham] and the Odyssey crew, because it’s so important not only to the rest of my life but to make sure that our kids are playing sports in the most safe and healthy way. It’s really important to talk about this and be in the proactive lane to be able to somehow solve this issue of head trauma and concussions in sport.”

To hear the full podcast, the full interview, visit https://ibn.fm/TGpqk

To view the full press release, visit https://ibn.fm/ML9WT

About Odyssey Health Inc. 

Odyssey Health is a medical company with a focus in the area of life-saving medical solutions. Odyssey’s corporate mission is to create, acquire and develop distinct assets, intellectual property, and exceptional technologies that provide meaningful medical solutions. The company is focused on areas that have an identified technological advantage, provide superior clinical utility, and have a substantial market opportunity.

 NOTE TO INVESTORS: The latest news and updates relating to ODYY are available in the company’s newsroom at https://ibn.fm/ODYY

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork